season
influenza
epidem
well
pandem
import
caus
mortal
morbid
world
health
organ
estim
season
influenza
result
million
case
sever
ill
death
annual
worldwid
avian
influenza
virus
continu
circul
poultri
popul
caus
intermitt
human
case
sinc
chan
respect
addit
sporad
human
case
avian
influenza
jiang
et
al
emerg
recent
year
number
differ
avian
influenza
virus
infect
human
concern
increas
probabl
strain
acquir
humantohuman
transmiss
capabl
make
emerg
influenza
pandem
like
trombetta
et
al
sever
influenza
defin
world
health
organ
clinic
radiograph
evid
lower
respiratori
tract
diseas
eg
dyspnoea
tachypnoea
radiograph
pneumonia
etc
central
nervou
system
involv
eg
encephalopathi
enceph
sever
dehydr
influenza
associ
certain
complic
eg
renal
failur
multiorgan
failur
septic
shock
rhabdomyolysi
myocard
influenza
caus
exacerb
underli
chronic
diseas
eg
asthma
chronic
obstruct
pulmonari
diseas
diabet
cardiovascular
condit
congest
cardiac
failur
condit
requir
hospit
admiss
howev
studi
simpli
defin
sever
influenza
influenza
requir
hospit
high
level
proinflammatori
cytokin
report
patient
sever
influenza
viru
infect
lee
et
al
bradleystewart
et
al
infect
peiri
et
al
de
jong
et
al
http
infect
chi
et
al
cytokin
may
caus
viral
infect
primari
cytokin
immun
respons
secondari
cytokin
guo
thoma
high
level
inflammatori
cytokin
often
call
cytokin
storm
cytokin
dysregul
though
difficult
discern
high
level
proinflammatori
respons
due
sever
diseas
dysregul
cytokin
respons
earli
antivir
therapi
neuraminidas
inhibitor
nai
associ
improv
outcom
patient
hospit
season
influenza
lee
et
al
lee
et
al
louie
et
al
muthuri
et
al
virus
adisasmito
et
al
signific
number
death
occur
despit
antivir
eg
mortal
despit
antivir
patient
admit
icu
influenza
louie
et
al
therefor
improv
antivir
may
suffici
strategi
minim
morbid
mortal
sever
influenza
given
role
inflamm
pathogenesi
use
adjunct
immunomodul
agent
remain
topic
great
interest
mani
patient
hospit
influenza
elderli
subject
comorbid
ill
requir
drug
treatment
immunomodul
properti
eg
statin
ppar
agonist
inhibitor
challeng
reli
retrospect
observ
studi
investig
effect
drug
clinic
outcom
sever
influenza
review
provid
updat
potenti
role
differ
immunomodulatori
agent
adjunct
therapi
manag
patient
hospit
sever
influenza
focu
rational
evid
use
agent
side
effect
agent
immunomodulatori
effect
direct
antivir
effect
also
discuss
search
public
english
medlin
embas
googl
scholar
decemb
use
search
term
influenza
combin
term
immunomodul
agent
adjunct
therapi
select
public
relev
clinic
treatment
classifi
immunomodul
agent
therapeut
procedur
therapi
evid
worsen
patient
outcom
therapi
uncertain
benefit
therapi
clinic
evid
improv
patient
outcom
system
corticosteroid
wide
prescrib
patient
influenza
complic
critic
ill
delaney
et
al
base
find
mark
elev
proinflammatori
cytokin
level
associ
high
mortal
rate
sever
influenza
viru
infect
due
de
jong
et
al
carter
viru
lee
et
al
mani
clinician
administ
corticosteroid
attempt
halt
diseas
progress
improv
clinic
outcom
except
small
number
studi
kudo
et
al
diaz
et
al
linko
et
al
major
observ
studi
shown
corticosteroid
therapi
often
presenc
delay
initi
nai
therapi
associ
higher
risk
death
increas
rate
nosocomi
pneumonia
develop
critic
diseas
compar
receiv
corticosteroid
therapi
martinloech
et
al
brunbuisson
et
al
kim
et
al
han
et
al
lee
et
al
tabl
studi
adjust
baselin
timevari
confound
worsen
clinic
statu
decis
time
start
corticosteroid
therapi
corticosteroid
therapi
use
alon
influenza
treatment
without
antivir
cover
han
et
al
corticosteroid
therapi
may
also
increas
risk
opportunist
infect
invas
aspergillosi
report
two
patient
infect
viru
receiv
high
dose
corticosteroid
ard
lat
et
al
emerg
na
mutat
observ
two
patient
viru
infect
given
corticosteroid
treatment
result
treatment
failur
fatal
outcom
addit
retrospect
cohort
studi
patient
receiv
corticosteroid
therapi
upper
respiratori
tract
infect
allergi
spinal
diseas
shown
within
one
month
drug
commenc
increas
rate
sepsi
incid
rate
ratio
ci
fractur
venou
thromboembol
decreas
subsequ
month
prednison
equival
dose
mgday
increas
risk
persist
incid
rate
ratio
sepsi
venou
thromboembol
fractur
walje
et
al
metaanalysi
data
studi
predominantli
relat
treatment
sever
influenza
viru
infect
shown
high
dose
corticosteroid
therapi
associ
increas
overal
mortal
ci
rodrigo
et
al
restrict
subgroup
studi
report
risk
adjust
mortal
still
ci
data
call
caution
liber
use
high
dose
corticosteroid
manag
patient
sever
influenza
two
studi
china
recent
examin
relationship
dosag
corticosteroid
mortal
viru
infect
comparison
control
highdos
corticosteroid
mgd
methylprednisolon
equival
associ
increas
risk
mortal
vs
p
mortal
vs
p
longer
durat
viral
shed
vs
day
p
patient
influenza
viral
pneumonia
differ
low
dose
mgd
methylprednisolon
control
cao
et
al
anoth
studi
patient
hospit
viru
infect
china
shown
corticosteroid
overal
influenc
either
mortal
subgroup
analysi
among
patient
pao
fio
mmhg
lowtomoderatedos
corticosteroid
treatment
equival
mgday
methylprednisolon
significantli
reduc
mortal
ahr
ci
mortal
ahr
ci
wherea
highdos
mgday
corticosteroid
therapi
yield
differ
current
lowdos
corticosteroid
eg
hydrocortison
mg
recommend
treatment
refractori
septic
shock
patient
sever
influenza
bautista
et
al
role
low
dose
adjuv
corticosteroid
patient
sever
influenza
great
interest
address
research
prioriti
well
design
rct
role
low
dose
corticosteroid
therapi
conduct
first
wave
next
influenza
pandem
uk
lim
et
al
nacetylcystein
nac
modifi
form
amino
acid
cystein
antioxid
properti
nac
shown
inhibit
product
proinflammatori
molecul
lung
epitheli
cell
infect
highli
pathogen
influenza
virus
geiler
et
al
inhibit
mucin
synthesi
proinflammatori
mediat
alveolar
type
ii
epitheli
cell
infect
influenza
virus
b
mata
et
al
murin
model
infect
influenza
viru
strain
adapt
mice
nac
demonstr
synergi
oseltamivir
protect
mice
lethal
influenza
infect
surviv
rate
combin
therapi
vs
oseltamivir
alon
garozzo
et
al
balbc
mice
inocul
intranas
virus
without
nac
nac
reduc
pulmonari
inflamm
pulmonari
edema
myeloperoxidas
activ
total
cell
neutrophil
macrophag
bronchoalveolar
lavag
bal
fluid
addit
nac
significantli
inhibit
level
protein
mrna
lung
pharmacolog
inhibitor
led
similar
effect
determin
nac
swine
influenza
virusinfect
mice
despit
scientif
basi
one
case
report
high
dose
nac
administ
mgkg
daili
continu
iv
infus
appear
effect
improv
clinic
statu
reduc
creactiv
protein
oxygen
requir
previous
healthi
femal
present
sever
pneumonia
septic
shock
due
influenza
howev
difficult
interpret
efficaci
nac
case
report
concomit
treatment
higher
licens
dose
oseltamivir
mg
twicedaili
nac
readili
avail
side
effect
cough
dyspnea
uncommon
tarrant
et
al
clinic
data
base
rct
design
need
evalu
role
nac
manag
sever
influenza
statin
competit
inhibitor
enzym
hmgcoa
reductas
commonli
prescrib
treatment
hypercholesterolemia
statin
antiinflammatori
immunomodulatori
effect
e
g
repress
induct
mhcii
interferon
ifn
subsequ
tlymphocyt
activ
weitzschmidt
et
al
jain
ridker
argu
statin
may
potenti
role
treatment
sever
influenza
fedson
number
studi
examin
effect
statin
influenza
mice
gener
neg
result
term
reduct
surviv
rate
viral
load
liu
et
al
radigan
et
al
belser
et
al
gluck
et
al
tabl
exampl
simvastatin
reduc
morbid
mortal
viral
load
mice
infect
either
virus
combin
simvastatin
oseltamivir
improv
effect
oseltamivir
alon
follow
infect
highli
pathogen
avian
influenza
viru
mice
despit
reduct
lung
cytokin
product
belser
et
al
anoth
studi
mice
infect
influenza
viru
simvastatin
given
oral
intraperiton
result
lower
surviv
rate
distinct
weight
loss
virusinfect
control
mice
furthermor
neither
viral
load
lung
trachea
histopatholog
lesion
reduc
simvastatin
treatment
gluck
et
al
epidemiolog
studi
patient
chronic
statin
develop
influenza
yield
gener
favor
result
term
protect
death
hospit
kwong
et
al
brett
et
al
vanderm
et
al
laidler
et
al
brassard
et
al
tabl
studi
uk
clinic
practic
research
datalink
identifi
patient
age
year
diagnos
influenzalik
ill
includ
statin
user
match
nonus
incid
hospit
death
among
statin
user
vs
nonus
result
lower
incid
statin
use
cumul
incid
ratio
ci
howev
protect
effect
statin
less
certain
among
new
user
concomit
chronic
ill
predispos
influenza
complic
respiratori
cardiac
diseas
data
suggest
benefici
effect
statin
influenzarel
advers
outcom
may
due
healthi
user
bia
brassard
et
al
multicent
trial
patient
sepsisassoci
ard
randomli
assign
receiv
either
enter
rosuvastatin
placebo
rosuvastatin
improv
clinic
outcom
patient
sepsisassoci
ard
might
contribut
hepat
renal
organ
dysfunct
nation
heart
lung
blood
institut
ard
clinic
trial
network
one
year
follow
cohort
shown
signific
differ
cumul
surviv
rosuvastatin
group
vs
placebo
vs
p
dingla
et
al
anoth
rct
adult
suspect
ventil
associ
pneumonia
shown
adjunct
simvastatin
therapi
reduc
mortal
comparison
placebo
papazian
et
al
current
publish
human
data
base
rct
acut
use
statin
manag
sever
influenza
drug
rel
cheap
readili
avail
research
warrant
examin
role
adjunct
therapi
anim
model
eg
mice
ferret
human
clinic
studi
major
side
effect
statin
includ
myopathi
rhabdomyolysi
liver
damag
type
diabet
allen
mamott
ongo
studi
evalu
atorvastatin
vs
placebo
addit
standard
care
decreas
inflammatori
marker
acut
influenza
clinicaltrialsgov
identifi
macrolid
antibiot
eg
erythromycin
clarithromycin
azithromycin
antiinflammatori
effect
addit
antibacteri
properti
vitro
shown
downregul
proinflammatori
cytokineschemokin
inhibit
signal
transduct
adhes
molecul
express
regul
inflammatori
cell
function
kanoh
rubin
zarogoulidi
et
al
parnham
et
al
cultur
human
tracheal
epitheli
cell
infect
influenza
virus
clarithromycin
reduc
viral
titer
cytokin
supernat
fluid
viral
rna
cell
clarithromycin
also
reduc
express
suscept
influenza
viru
infect
apart
reduc
express
sialic
acid
tracheal
mucos
surfac
number
fluoresc
intens
acid
endosom
cell
viral
rnp
enter
cytoplasm
yamaya
et
al
vitro
model
use
mardindarbi
canin
kidney
mdck
cell
human
lung
epitheli
cell
clarithromycin
show
decreas
intracellular
viral
replic
via
inhibit
viral
protein
product
miyamoto
et
al
limit
data
base
murin
model
suggest
macrolid
could
reduc
cytokin
product
sever
pneumonia
kanoh
rubin
min
jang
effect
macrolid
human
infect
influenza
virus
shown
tabl
patient
mild
season
influenza
without
pneumonia
addit
clarithromycin
led
shorter
durat
cough
patient
without
cough
onset
pyrexia
ishii
et
al
addit
azithromycin
oseltamivir
patient
influenza
without
pneumonia
led
lower
maximum
temperatur
monogroup
day
p
without
signific
differ
express
level
inflammatori
cytokin
chemokin
group
kakeya
et
al
util
macrolid
evalu
observ
studi
critic
ill
patient
spain
infect
influenza
primari
viral
pneumonia
without
secondari
infect
patient
macrolidebas
treatment
lower
icu
mortal
univari
analysi
vs
p
howev
propens
score
analysi
show
effect
macrolidebas
treatment
icu
mortal
ci
p
martinloech
et
al
separ
multicent
trial
adult
hospit
laboratoryconfirm
influenza
particip
random
receiv
oseltamivirazithromycin
n
oseltamivir
alon
n
group
faster
reduct
plasma
concentr
proinflammatori
cytokin
crp
oseltamivirazithromycin
group
reduct
plasma
concentr
baselin
vs
vs
vs
vs
respect
compar
oseltamivirazithromycin
group
vs
oseltamivir
monotherapi
trend
toward
faster
symptom
resolut
differ
viral
rna
declin
p
cultureneg
rate
addit
ex
vivo
studi
confirm
reduc
induct
p
p
azithromycin
find
demonstr
azithromycin
reduc
cytokin
level
impair
viral
clearanc
major
side
effect
macrolid
includ
diarrhea
leucopenia
deaf
increas
risk
cardiovascular
death
elderli
subject
high
baselin
risk
cardiovascular
diseas
ray
et
al
role
tripl
combin
therapi
oseltamivir
clarithromycin
naproxen
discuss
section
ppar
agonist
group
medic
act
peroxisom
proliferatoractiv
receptor
apart
clinic
use
lipidlow
activ
evid
gemfibrozil
agonist
inhibit
product
proinflammatori
cytokin
calkin
et
al
sever
studi
budd
et
al
bauer
et
al
aldridg
et
al
base
mice
model
show
antiinflammatori
effect
agonist
influenza
viru
infect
surviv
advantag
tabl
tnf
induc
nitric
oxid
synthas
produc
dendrit
cell
tipdc
accumul
lung
signific
number
lethal
influenza
infect
acquir
process
present
influenza
antigen
context
mhc
class
antigen
cell
aldridg
et
al
lethal
influenza
infect
chemokin
accumul
significantli
higher
level
airway
result
increas
recruit
tipdc
piglitazon
diminish
tipdc
recruit
allow
protect
tcell
expans
smoke
exposur
prior
influenza
infect
shown
increas
lung
inflamm
influenza
infect
robbin
et
al
pioglitazon
significantli
attenu
exagger
inflamm
observ
smokeexpos
influenza
infect
mice
bauer
et
al
us
food
drug
administr
fda
commun
potenti
cardiovascular
risk
thiazolidinedion
rosiglitazon
pioglitazon
requir
risk
evalu
mitig
strategi
rem
rosiglitazon
also
commun
potenti
risk
bladder
cancer
pioglitazon
use
hsu
et
al
role
altern
antiinflammatori
drug
agonist
explor
treatment
sever
influenza
anim
model
clinic
util
may
limit
toxic
combin
statin
caffein
amelior
lung
damag
inhibit
viral
replic
appear
least
effect
oseltamivir
ribavirin
howev
statincaffein
combin
seem
effect
administ
prevent
rather
treatment
radigan
et
al
murin
model
influenza
viru
infect
administr
rosuvastatin
effect
viral
clearanc
infect
mortal
belser
et
al
mice
infect
virus
simvastatin
reduc
morbid
mortal
viral
load
combin
simvastatin
oseltamivir
improv
effect
oseltamivir
alon
follow
highli
pathogen
avian
influenza
viru
infect
mice
despit
modest
reduct
lung
cytokin
product
gluck
et
al
studi
evalu
efficaci
simvastatin
influenza
apr
viru
infect
balbcmic
first
studi
simvastatin
administ
oral
achiev
high
plasma
level
intraperiton
applic
use
second
studi
treatment
simvastatin
result
lower
surviv
rate
distinct
bodi
mass
loss
comparison
virusinfect
control
mice
furthermor
viral
load
lung
trachea
well
histopatholog
lesion
reduc
simvastatin
b
human
epidemiolog
studi
kwong
et
al
populationbas
cohort
studi
influenza
season
ontario
canada
propensitybas
match
studi
hospit
adult
state
usa
influenza
season
analyz
evalu
associ
receiv
statin
influenzarel
death
statin
treatment
hospit
associ
protect
adjust
oddsofdeath
ci
follow
adjust
age
race
comorbid
diseas
influenza
vaccin
antivir
administr
laidler
et
al
studi
use
populationbas
influenza
hospit
surveil
data
propens
scorematch
analysi
cox
regress
determin
associ
mortal
within
day
posit
influenza
test
statin
treatment
among
hospit
cohort
influenza
season
incid
hospit
death
statin
user
vs
nonus
result
lower
incid
statin
use
cumul
incid
ratio
ci
howev
protect
effect
statin
less
pronounc
among
new
user
concomit
chronic
ill
predispos
influenza
complic
respiratori
cardiac
diseas
ds
hui
et
al
antivir
research
tabl
effect
macrolid
human
influenza
infect
author
kakeya
et
al
prospect
random
clinic
trial
oseltamivir
n
vs
oseltamivir
azithromycin
combin
therapi
n
influenza
without
pneumonia
signific
differ
express
level
inflammatori
cytokin
chemokin
group
maximum
temperatur
combogroup
lower
monogroup
p
particularli
p
lee
et
al
rct
patient
random
oseltamivirazithromycin
n
oseltamivir
group
n
similar
baselin
characterist
age
year
faster
reduct
proinflammatori
cytokin
crp
oseltamivirazithromycin
group
trend
toward
faster
symptom
resolut
differ
viral
rna
declin
p
cultureneg
rate
addit
ex
vivo
studi
confirm
reduc
induct
p
p
azithromycin
ds
hui
et
al
antivir
research
nitazoxanid
nitazoxanid
ntz
oral
antiparasit
drug
antivir
immunomodulatori
effect
antivir
activ
ntz
circul
metabolit
tizoxanid
demonstr
sever
cell
line
infect
influenza
influenza
b
viru
rossignol
tizoxanid
inhibit
replic
influenza
virus
posttransl
level
select
block
matur
viral
hemagglutinin
stage
preced
resist
endoglycosidas
h
digest
thu
impair
hemagglutinin
intracellular
traffick
insert
host
plasma
membran
rossignol
et
al
antiinflammatori
effect
includ
upregul
ifn
variou
ifninduc
gene
rossignol
vitro
data
show
synergist
effect
ntz
oseltamivir
influenza
virus
belardo
et
al
phase
studi
low
risk
acut
uncompl
influenza
b
age
year
without
underli
medic
condit
put
high
risk
complic
subject
random
receiv
ntz
mg
bd
ntz
mg
bd
placebo
treatment
ntz
mg
bd
day
associ
reduct
durat
symptom
h
compar
placebo
h
ci
p
wherea
mg
bd
cohort
significantli
differ
control
h
p
haffizulla
et
al
influenzainfect
subject
receiv
ntz
mg
also
show
signific
reduct
viral
titer
studi
day
vs
placebo
group
p
resist
observ
influenza
virus
collect
ntztreat
subject
advers
effect
humor
immun
respons
observ
advers
event
similar
among
three
treatment
group
haffizulla
et
al
recent
complet
studi
ntz
vs
oseltamivir
treatment
acut
uncompl
influenza
clinicaltrialsgov
identifi
ntz
oseltamivir
design
acut
uncompl
influenza
clinicaltrialsgov
identifi
ntz
vs
placebo
standard
care
sever
acut
respiratori
ill
sari
clinicaltrialsgov
identifi
data
avail
studi
time
data
studi
public
appropri
peer
review
use
studi
ntz
treatment
influenza
caution
chloroquin
antimalari
drug
act
rais
lysosom
ph
lead
inhibit
fusion
autophagosom
lysosom
lysosom
protein
degrad
chloroquin
vitro
activ
influenza
strain
concentr
achiev
vivo
dose
use
malaria
prophylaxi
treatment
connectivetissu
diseas
ooi
et
al
di
trani
et
al
chloroquin
prevent
influenza
infect
diminish
weight
loss
mice
infect
mouseadapt
influenza
strain
minim
activ
limit
viral
replic
ferret
infect
adapt
strain
vigerust
mcculler
chloroquin
inhibit
autophagi
mous
lung
induc
viral
load
proinflammatori
cytokin
significantli
affect
major
side
effect
chloroquin
human
includ
headach
diarrhea
nausea
blur
vision
furthermor
prevent
influenza
infect
healthi
commun
popul
paton
et
al
limit
publish
data
put
chloroquin
deriv
lower
prioriti
evalu
candid
drug
clinic
treatment
sever
influenza
pamidron
bisphosphon
use
clinic
treatment
hypercalcemia
paget
diseas
siri
et
al
pamidron
exhibit
protect
effect
influenza
infect
caus
season
influenza
avian
virus
vitro
vivo
model
antivir
effect
pamidron
depend
cell
mediat
cytokin
secret
cytotox
virusinfect
host
cell
tu
et
al
qin
et
al
earli
treatment
intraperiton
pamidron
reduc
morbid
mortal
infect
mice
control
viral
replic
inflamm
affect
lung
delay
treatment
pamidron
start
day
infect
could
still
reduc
diseas
sever
infect
mice
improv
chanc
surviv
wherea
oral
oseltamivir
start
time
show
therapeut
effect
antivir
effect
pamidron
partli
mediat
secret
human
cell
human
cell
could
directli
kill
virusinfect
host
cell
perforin
granzym
band
manner
zheng
et
al
major
side
effect
pamidron
includ
acut
system
inflammatori
reaction
ocular
inflamm
renal
failur
nephrot
syndrom
electrolyt
imbal
osteonecrosi
maxilla
mandibl
tanvetyanon
stiff
atyp
femor
fractur
powel
et
al
given
potenti
side
effect
pamidronatebas
therapi
would
high
prioriti
candid
clinic
trial
treatment
sever
influenza
infect
complement
cleavag
peptid
may
trigger
tabl
studi
effect
ppar
agonist
influenza
infect
mice
studi
design
key
find
budd
et
al
mice
given
gemfibrozil
intraperiton
mgkg
daili
n
day
follow
intranas
infect
compar
control
group
surviv
balbc
mice
infect
influenza
viru
increas
vehicletr
mice
n
mice
given
gemfibrozil
bauer
et
al
studi
examin
effect
system
corticosteroid
dexamethason
vs
agonist
pioglitazon
outcom
influenza
mice
expos
room
air
cigarett
smoke
day
inocul
mous
adapt
viru
mimic
influenza
copd
smokeexpos
mice
note
exacerb
inflammatori
respons
follow
infect
dexamethason
treatment
reduc
mononuclear
cell
bronchoalveolar
lavag
bal
smokeexpos
virusinfect
mice
pioglitazon
reduc
mononuclear
cell
neutrophil
bal
increas
peripher
cell
aldridg
et
al
mice
challeng
virul
influenza
virus
includ
circul
avian
strain
increas
select
accumul
particular
dendrit
cell
dc
subset
tnfinosproduc
tip
dc
note
airway
mice
pneumonia
tipdc
appear
requir
prolifer
influenzaspecif
cell
infect
lung
block
recruit
mice
decreas
number
effector
reduc
viru
clearanc
howev
treatment
agonist
pioglitazon
reduc
tipdc
traffick
might
moder
potenti
lethal
consequ
excess
tipdc
recruit
without
abrog
cell
expans
compromis
viru
control
ds
hui
et
al
antivir
research
format
neutrophil
extracellular
trap
net
releas
histon
protein
extracellular
compart
acut
lung
injuri
ali
ard
net
may
activ
platelet
releas
involv
tissu
remodel
later
phase
aliard
bosmann
ward
follow
inocul
african
green
monkey
virus
treatment
intraven
mgkg
novel
neutral
specif
antihuman
antibodi
min
viru
inocul
treatment
infect
monkey
led
reduct
ali
reduct
lung
histopatholog
injuri
less
lung
infiltr
macrophag
neutrophil
monkey
sacrif
day
also
decreas
system
inflammatori
respons
reduct
viru
titer
infect
lung
sun
et
al
ali
includ
impair
alveolar
fluid
clearanc
seriou
complic
sever
respiratori
viru
infect
vitro
influenza
infect
impair
alveolar
fluid
clearanc
much
season
viru
impair
mediat
releas
solubl
factor
infect
cell
lead
downregul
alveolar
na
cl
transport
mesenchym
stromal
cell
msc
prevent
reduc
effect
vitro
vivo
infect
age
mice
secret
solubl
paracrin
growth
factor
kgf
howev
mice
infect
influenza
apuerto
mouseadapt
viru
influenza
swineorigin
pandem
viru
administ
human
mous
msc
via
tail
vein
either
preor
postinfect
regimen
fail
improv
surviv
decreas
pulmonari
inflammationinflammatori
cell
count
prevent
ali
msc
administ
combin
oseltamivir
also
fail
improv
outcom
darwish
et
al
anoth
studi
mice
infect
intranas
viru
induc
ali
msc
treatment
significantli
reduc
induc
ali
associ
reduc
pulmonari
inflamm
msc
promot
antiinflammatori
highli
phagocyt
macrophag
phenotyp
extracellular
vesicl
ev
mediat
mitochondri
transfer
ard
mscinduc
chang
macrophag
phenotyp
critic
depend
enhanc
macrophag
oxid
phosphoryl
murin
alveolar
macrophag
treat
mscderiv
ev
amelior
lung
injuri
vivo
morrison
et
al
work
need
anim
model
eg
mice
ferret
examin
role
msc
combin
antivir
treatment
ali
sever
influenza
mycophenol
acid
prodrug
mycophenol
mofetil
mmf
wide
use
immunomodulatori
agent
transplant
recipi
patient
autoimmun
diseas
villarroel
et
al
volkmann
et
al
mycophenol
acid
broadspectrum
vitro
antivir
activ
influenza
b
virus
cellprotect
assay
antivir
effect
mycophenol
acid
complet
revert
guanosin
supplement
plaqu
reduct
assay
show
mycophenol
acid
antivir
activ
multipl
clinic
isol
influenza
b
virus
studi
examin
antivir
activ
mmf
viru
infect
use
mdck
cell
mice
ic
mmf
similar
zanamivir
virusinfect
mdck
cell
base
elisa
interestingli
mmf
inhibit
viral
mrna
replic
protein
express
complet
h
timecours
assay
follow
commenc
treatment
addit
mice
surviv
viral
titer
lung
markedli
reduc
mmf
treatment
cho
et
al
protect
mechan
mmf
viru
infect
due
inhibit
cellular
inosin
monophosph
dehydrogenas
impdh
exogen
guanosin
inhibit
viral
mrna
protein
express
moreov
mrna
express
level
substanti
downregul
mdck
cell
mmf
treatment
cho
et
al
import
note
mmf
good
inhibitori
effect
middl
east
respiratori
syndrom
coronaviru
vitro
marmoset
treat
mmf
develop
sever
andor
fatal
diseas
higher
mean
viral
load
untreat
anim
work
need
mice
ferret
model
understand
potenti
role
mycophenol
acid
treatment
sever
influenza
rct
rel
mildli
affect
patient
age
yr
hospit
influenza
without
pneumonia
signific
reduct
estim
median
time
fever
resolut
seen
oseltamivir
maxingshiganyinqiaosan
combin
oseltamivir
vs
control
group
ephedra
main
ingredi
biolog
effect
due
ephedrin
pseudoephedrin
content
time
fever
resolut
reduc
ci
p
compar
oseltamivir
vs
oseltamivir
alon
howev
signific
differ
symptom
score
data
serial
viral
kinet
avail
anoth
rct
patient
age
yr
uncompl
influenza
found
signific
differ
patient
treat
herbal
medicin
lianhuaqingwen
capsul
lhc
oseltamivir
term
median
durat
ill
lhc
h
vs
oseltamivir
h
p
median
durat
viral
shed
lhc
h
vs
oseltamivir
h
p
duan
et
al
cochran
review
role
chines
medicin
herb
influenza
base
studi
particip
conclud
methodolog
qualiti
major
studi
poor
high
qualiti
rct
larger
sampl
size
need
evalu
therapeut
role
herbal
medicin
select
inhibitor
nonsteroid
antiinflammatori
drug
nsaid
target
induc
enzym
respons
inflammatori
process
immun
respons
inhibitor
shown
suppress
viru
replic
human
macrophag
lee
et
al
effect
inhibitor
influenza
viral
infect
examin
mice
given
inhibitor
inhibitor
celecoxib
inhibitor
begin
week
prior
influenza
viral
infect
pfu
throughout
cours
experi
treatment
significantli
increas
mortal
associ
profound
hypothermia
greater
weight
loss
celecoxib
control
group
level
tnfa
gcsf
significantli
attenu
celecoxib
group
vs
control
level
much
lower
bal
fluid
celecoxibtr
mice
vs
control
vs
group
carey
et
al
effect
celecoxib
combin
mesalazin
zanamivir
assess
balbc
mice
challeng
influenza
viru
treatment
start
h
viral
inocul
simul
reallif
scenario
zheng
et
al
surviv
rate
surviv
time
improv
group
receiv
zanamivir
celecoxib
mesalazin
compar
zanamivir
alon
significantli
higher
level
cell
less
pulmonari
inflamm
also
note
group
receiv
tripl
therapi
zanamivir
alon
reduc
viral
load
without
signific
effect
lung
inflamm
mortal
mesalazin
inhibit
lipoxygenas
cox
pathway
lead
reduct
proinflammatori
cytokin
eicosanoid
therefor
deactiv
inflammatori
cell
macrophag
neutrophil
zheng
et
al
studi
balbc
mice
inocul
intranas
viru
isol
chicken
wet
market
epidemiolog
link
fatal
human
case
heavi
alveolar
inflamm
pulmonari
hemorrhag
associ
high
pulmonari
level
proinflammatori
cytokin
mous
lung
cell
line
also
induc
high
level
mrna
administr
antivir
zanamivir
significantli
improv
surviv
mice
infect
coadministr
celecoxib
combin
zanamivir
improv
surviv
lung
patholog
import
note
use
nsaid
episod
acut
respiratori
infect
especi
parenter
nsaid
associ
increas
risk
acut
myocardi
infarct
wen
et
al
clinic
studi
need
therapeut
role
inhibitor
combin
nai
immunomodul
agent
treatment
sever
influenza
section
type
ifn
eg
type
iii
interferon
import
mediat
innat
immun
respons
influenza
viru
infect
hsu
et
al
recognit
influenza
viral
compon
tolllik
receptor
tlr
eg
andor
retino
acidinduc
gene
melanoma
differenti
associ
crotta
et
al
upregul
express
type
type
iii
ifn
induc
numer
ifnstimul
gene
isg
result
viral
restrict
activ
adapt
immun
respons
durbin
et
al
patient
hospit
sever
influenza
evid
defici
innat
immun
respons
lower
plasma
level
monocyt
chemoattract
agrati
et
al
fatal
case
unabl
mount
suffici
serolog
respons
earli
guihot
et
al
innat
immun
respons
influenza
virus
involv
product
play
import
role
viru
clearanc
initi
stage
infect
ifn
receptor
knockout
mice
type
ifn
respons
direct
resolut
viral
load
limit
acut
lung
injuri
suppress
immunopatholog
caus
influenza
viru
via
product
arimori
et
al
lowdos
protect
mice
lethal
viral
infect
also
effect
viru
vitro
mice
haasbach
et
al
intro
studi
shown
antivir
agent
differ
mechan
action
season
influenza
virus
eg
oseltamivir
combin
exert
significantli
greater
synergist
effect
cotreat
drug
target
signal
pathway
ie
plu
vitro
ilyushina
donnelli
thu
combin
exogen
ifn
plu
oseltamivir
may
potenti
therapi
treat
influenza
infect
systemat
review
metaanalysi
anim
studi
involv
mice
chick
shown
treatment
antipyret
includ
aspirin
paracetamol
diclofenac
influenza
infect
increas
risk
mortal
pool
odd
ratio
eyer
et
al
howev
rct
shown
earli
administr
intraven
acetaminophen
g
vs
placebo
treatment
fever
due
probabl
infect
affect
number
icufre
day
mortal
rate
day
day
young
et
al
anoth
rct
patient
age
yr
shown
regular
paracetamol
g
qid
vs
oral
placebo
day
effect
viral
shed
temperatur
clinic
symptom
patient
influenza
confirm
pcr
jefferi
et
al
polymyxin
pmx
bimmobil
fiber
column
first
introduc
japan
extracorpor
devic
use
pmxb
fix
polystyrenederiv
fiber
remov
circul
endotoxin
reduc
variou
cytokin
direct
hemoperfus
ronco
klein
three
case
report
suggest
pmx
column
hemoperfus
could
reduc
hypercytokinemia
elev
interferongamma
highmobl
group
improv
clinic
outcom
patient
takeda
et
al
binh
et
al
viru
infect
kudo
et
al
complic
ard
despit
treatment
nai
suggest
treatment
pmx
hemoperfus
oseltamivir
effect
improv
ard
due
influenza
initi
earli
binh
et
al
therapeut
plasma
exchang
tpe
plasmapheresi
extracorpor
blood
purif
techniqu
design
remov
largemolecularweight
substanc
plasma
pediatr
case
seri
describ
three
children
age
yr
sever
influenza
complic
ard
hemodynam
instabl
requir
invas
mechan
ventil
inhal
nitric
oxid
extracorpor
membran
oxygen
one
patient
patel
et
al
tpe
provid
rescu
strategi
patient
dramat
subsequ
reduct
blood
lactat
level
oxygen
requir
inotrop
support
pediatr
logist
organ
dysfunct
score
patient
made
good
function
recoveri
difficult
judg
therapeut
effect
pmx
bimmobil
fiber
column
hemoperfus
tpe
base
find
uncontrol
case
report
especi
concomit
use
nai
sinc
behr
demonstr
first
use
passiv
immunotherapi
treat
diphtheria
tetanu
behr
kitasato
plasma
use
treat
sever
infecti
diseas
includ
spanish
flu
luke
et
al
sever
acut
respiratori
syndrom
sar
soo
et
al
middl
east
respiratori
syndrom
mer
mo
fisher
recent
ebola
epidem
west
africa
van
griensven
et
al
therefor
surpris
modal
use
treat
sever
influenza
immun
globulin
intraven
use
ivig
contain
concentr
globulin
prepar
made
pool
human
plasma
gelfand
ivig
sever
benefit
plasma
treatment
ivig
given
smaller
volum
thu
less
concern
fluid
overload
abo
blood
match
need
ivig
provid
uniform
product
compar
individu
plasma
unit
differ
antibodi
titer
presum
function
compon
immun
plasma
ivig
igg
fraction
igg
may
effect
howev
either
nonspecif
immun
modulatori
effect
igg
constant
fragment
fc
fragment
dimer
antigen
bind
fragment
f
ab
fragment
schwab
nimmerjahn
fc
fragment
import
proinflammatori
activ
igg
humor
arm
cellular
arm
innat
immun
system
igg
fc
fragment
may
also
play
role
antiinflammatori
effect
howev
influenza
model
protect
also
afford
purifi
f
ab
fc
fragment
deriv
ivig
support
specif
antibodymedi
mechan
protect
rather
immun
modul
rockman
et
al
prior
studi
compar
f
ab
fragment
whole
nonimmun
igg
shown
f
ab
fragment
suffici
protect
nonimmun
antibodi
protect
lu
et
al
plasma
therapi
use
plasma
patient
fulli
recov
vaccin
infect
treat
infect
one
metaanalysi
review
report
influenza
pandem
suggest
earli
administr
convalesc
blood
product
reduc
risk
death
pneumonia
overal
mortal
reduc
ci
luke
et
al
convalesc
plasma
administ
adjunct
treatment
favor
outcom
patient
china
sever
influenza
pneumonia
multiorgan
failur
despit
highdos
oseltamivir
zhou
et
al
anoth
patient
sever
infect
progress
ard
despit
treatment
standard
dose
oseltamivir
prospect
multicent
casecontrol
studi
evalu
use
convalesc
plasma
sever
influenza
hung
et
al
ninetythre
particip
clinic
deterior
despit
optim
antivir
treatment
requir
intens
care
enrol
subject
offer
immun
plasma
neutral
antibodi
titer
particip
accept
plasma
compar
subject
accept
plasma
mortal
group
accept
plasma
vs
declin
control
arm
mortal
higher
anticip
similar
sever
ill
duggal
et
al
howev
author
conclud
plasma
effect
reduc
mortal
respiratori
tract
viral
load
serum
cytokin
level
treatment
group
phase
studi
patient
usa
sever
influenza
b
hypoxia
tachypnea
randomli
assign
either
unit
pediatr
equival
convalesc
plasma
hai
titer
least
plu
standard
care
standard
care
alon
receiv
antivir
oseltamivir
monotherapi
studi
show
differ
primari
endpoint
normal
respiratori
statu
day
vs
p
beigel
et
al
multipl
secondari
endpoint
also
uniformli
conclus
includ
fewer
day
hospit
random
median
vs
p
fewer
particip
hospit
readmiss
vs
p
fewer
particip
icu
admiss
vs
p
fewer
day
mechan
ventil
median
vs
p
disposit
hospit
discharg
p
clinic
statu
day
death
icu
hospit
oxygen
hospit
oxygen
hospit
return
normal
activ
hospit
return
normal
activ
p
transfusionrel
acut
lung
injuri
trali
transfus
associ
circulatori
overload
taco
potenti
life
threaten
studi
underpow
result
support
develop
larger
ongo
plasma
treatment
studi
use
clinic
statu
day
ordin
scale
primari
endpoint
clinicaltrialsgov
identifi
vitro
studi
shown
standard
human
ivig
lot
manufactur
often
detect
hai
neutral
antibodi
titer
circul
noncircul
strain
kubotakoketsu
et
al
tian
et
al
onodera
et
al
tabl
undilut
ivig
typic
protein
eg
ml
roughli
igg
typic
serum
concentr
undilut
ivig
moder
hai
neutral
titer
eg
hai
noncircul
kubotakoketsu
et
al
though
dilut
physiolog
concentr
titer
noncircul
strain
closer
hong
et
al
studi
use
ferret
shown
ivig
administ
time
influenza
viru
exposur
led
signific
reduct
lung
viral
load
follow
challeng
ferret
viru
lethal
influenza
model
major
ferret
given
ivig
surviv
challeng
dose
depend
manner
rockman
et
al
high
dose
standard
ivig
gkg
given
kawasaki
diseas
shown
increas
microneutr
mn
titer
recipi
hai
titer
howev
dose
practic
may
carri
risk
thrombosi
renal
dysfunct
gammunex
packag
insert
interest
turn
immun
ivig
product
plasma
use
manufactur
ivig
chosen
certain
attribut
high
titer
antiinfluenza
antibodi
call
hyperimmun
ivig
protect
efficaci
ivig
manufactur
human
plasma
collect
influenza
pandem
due
viru
postpandem
immun
ivig
prepar
evalu
scid
mous
challeng
model
postpandem
immun
ivig
hi
titer
provid
complet
protect
lethal
scid
mice
viru
challeng
mice
surviv
day
postchalleng
vs
mice
surviv
prepandem
ivig
hi
titer
group
vs
surviv
buffer
control
group
mice
administ
dilut
ivig
undilut
protect
dose
depend
highli
signific
correl
circul
vivo
hi
mn
antibodi
titer
mice
surviv
nonparametr
spearman
correl
r
p
hohenadl
et
al
rct
patient
hospit
sever
viru
infect
hospit
hong
kong
compar
treatment
immun
ivig
prepar
plasma
person
recov
diseas
treatment
normal
ivig
manufactur
hung
et
al
thirtyf
patient
sever
influenza
infect
standard
antivir
treatment
requir
intens
care
ventil
support
random
receiv
immun
ivig
patient
nonimmun
ivig
patient
immun
ivig
treatment
associ
significantli
lower
day
posttreat
viral
load
compar
control
p
p
respect
subgroup
multivari
analysi
patient
receiv
treatment
within
day
symptom
onset
demonstr
immun
ivig
treatment
factor
independ
reduc
mortal
ci
p
hung
et
al
ongo
studi
evalu
immun
ivig
vs
placebo
addit
standard
care
patient
hospit
sever
influenza
use
clinic
statu
day
ordin
scale
primari
endpoint
clinicaltrialsgov
identifi
phase
rct
adult
hospit
infect
shown
tripl
combin
treatment
day
clarithromycin
mg
naproxen
mg
oseltamivir
mg
twice
daili
follow
day
oseltamivir
reduc
vs
mortal
vs
hospit
length
stay
vs
oseltamivir
mg
twice
daili
without
placebo
day
control
hung
et
al
multivari
analysi
show
tripl
combin
therapi
independ
factor
associ
lower
mortal
ci
p
find
associ
significantli
faster
reduct
viral
load
pneumonia
sever
index
fewer
patient
nairesist
viru
quasispeci
detect
hung
et
al
howev
studi
design
allow
assess
possibl
individu
contribut
naproxen
clarithromycin
larger
confirmatori
studi
includ
patient
present
later
ill
high
prioriti
readili
avail
combin
naproxen
inhibit
viru
replic
interf
bind
viru
rna
nucleoprotein
lejal
et
al
sirolimu
also
known
rapamycin
macrolid
compound
inhibitori
effect
mechanist
target
rapamycin
mtor
pathway
mtor
play
central
role
regul
mani
fundament
cell
process
protein
synthesi
autophagi
deregul
mtor
signal
implic
progress
cancer
diabet
well
age
process
saxton
sabatini
sever
gene
phosphatidylinositol
aktmtor
pathway
shown
support
broadspectrum
viral
replic
includ
influenza
vitro
rna
interfer
everolimu
mtor
inhibitor
vitro
antivir
activ
influenza
viru
lethal
mous
infect
model
influenza
viru
infect
everolimu
treatment
mgkgday
significantli
delay
death
although
could
prevent
mortal
histopatholog
find
show
decreas
pulmonari
hemorrhag
lung
weight
everolimu
treat
mice
respons
infect
mous
model
sirolimu
given
time
influenza
viru
inocul
continu
day
mice
treat
sirolimu
bodi
weight
loss
ill
higher
viral
load
day
control
receiv
sirolimu
howev
trend
suggest
lower
lung
inflamm
score
seen
histolog
specimen
mean
score
vs
p
improv
complianc
mechan
ventil
mice
receiv
sirolimu
consist
drugpromot
apoptosi
lower
experiment
lung
injuri
associ
influenza
infect
alsuwaidi
et
al
openlabel
prospect
rct
critic
ill
patient
infect
influenza
requir
invas
mechan
ventil
imv
addit
sirolimu
mgd
day
oseltamivir
mg
bd
day
prednisolon
mgd
day
n
associ
higher
frequenc
liber
imv
vs
p
shorter
durat
imv
vs
day
p
higher
chanc
achiev
lrt
viral
rna
neg
day
vs
p
compar
treat
oseltamivir
prednisolon
without
addit
sirolimu
n
howev
studi
collect
serial
sampl
quantit
virolog
assess
immunolog
impact
ie
serum
bronchoalveolar
lavag
cytokin
level
intervent
advers
effect
sirolimu
everolimu
includ
leukopenia
thrombocytopenia
diarrhea
stomat
hypercholesterolemia
rare
interstiti
pneumon
moe
et
al
current
immunomodulatori
agent
conclus
proven
benefit
sever
influenza
passiv
immunotherapi
form
convalesc
plasma
immun
ivig
may
use
adjunct
therapi
sever
influenza
definit
studi
ongo
tripl
combin
oseltamivir
clarithromycin
naproxen
sever
influenza
demonstr
effect
one
rct
find
need
confirm
likewis
sirolimu
use
appar
benefit
critic
ill
influenza
patient
context
rct
confirmatori
studi
approach
without
concomit
corticosteroid
therapi
explor
research
prioriti
efficaci
agent
potenti
immunomodul
effect
includ
nac
acut
use
statin
macrolid
pamidron
ntz
ifn
chloroquin
antibodi
human
mesenchym
stromal
cell
ppar
agonist
cox
inhibitor
mesalazin
herbal
medicin
role
plasmapheresi
pmx
hemoperfus
rescu
therapi
deserv
investig
prefer
rct
system
corticosteroid
administ
high
dose
may
increas
risk
mortal
morbid
patient
sever
influenza
use
role
low
dose
system
corticosteroid
requir
evalu
research
prioriti
project
fund
whole
part
feder
fund
nation
cancer
institut
nation
institut
health
contract
content
public
necessarili
reflect
view
polici
depart
health
human
servic
mention
trade
name
commerci
product
organ
impli
endors
us
govern
supplementari
data
relat
articl
found
http
dx
studi
analyz
prepandem
ivig
sera
kawasaki
diseas
patient
receiv
ivig
standard
treatment
autoimmun
vascul
virusspecif
antibodi
microneutr
hemagglutin
inhibit
ivig
prepar
test
signific
level
crossreact
specif
antibodi
concentr
gdl
immunoglobulin
sera
kawasaki
diseas
patient
signific
increas
crossreactivespecif
antibodi
receiv
gkg
prepandem
ivig
kubotakoketsu
et
al
vitro
studi
human
ivig
manufactur
japan
signific
neutral
activ
influenza
virus
observ
lot
human
ivig
tian
et
al
studi
analyz
sera
healthi
adult
donor
southern
china
commerci
avail
ivig
manufactur
microneutr
test
titer
neutral
antibodi
nab
sever
common
respiratori
virus
includ
respiratori
syncyti
viru
rsv
season
influenza
enteroviru
coxsackieviru
high
proport
sampl
healthi
adult
posit
nab
virus
except
differ
proport
sampl
high
nab
titer
influenza
rsv
adenoviru
type
adenoviru
type
commerci
avail
ivig
found
high
nab
titer
influenza
rockman
et
al
studi
examin
potenti
human
ivig
amelior
influenza
infect
ferret
expos
either
highli
pathogen
avian
influenza
viru
ivig
administ
time
influenza
viru
exposur
led
signific
reduct
lung
viral
load
follow
challeng
ferret
viru
lethal
model
major
ferret
given
ivig
surviv
challeng
dose
depend
manner
protect
also
afford
purifi
f
fc
fragment
deriv
ivig
support
specif
antibodymedi
mechan
protect
onodera
et
al
studi
variat
hemagglutin
inhibit
hi
neutral
antibodi
titer
season
influenza
virus
b
influenza
viru
strain
ivig
lot
manufactur
examin
addit
import
monitor
reactiv
ivig
season
influenza
virus
vari
antigen
evalu
ivig
manufactur
exhibit
signific
hi
mn
titer
vs
investig
strain
season
influenza
ds
hui
et
al
antivir
research
